Biotech startup, which has raised more than $200M in VC funding, launches clinical trial for cancer drug

View Content

Founded in 2018, Wugen is developing “off the shelf” cell therapies to treat various cancers. The startup was created via technology licensed from Washington University and is developing so-called natural killer (NK) and T-cell therapies.

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *